Dr. Brugarolas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2542- Is this information wrong?
Summary
Clinical Expertise
- Kidney Neoplasms, Renal cell carcinoma, Urologic oncology, Hematologic oncology
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2003
- Duke University HospitalResidency, Internal Medicine, 1998 - 2001
- Massachusetts Institute of TechnologyPhD, Biology, 1993 - 1998
- Universidad de Navarra Faculty of MedicineClass of 1993
Certifications & Licensure
- TX State Medical License 2006 - 2026
- MA State Medical License 2002 - 2007
- NC State Medical License 1998 - 2004
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Principal Investigator, Kidney Cancer Specialized Program of Research Excellence (SPORE) National Cancer Institute
- Elected to the American Society for Clinical Investigation 2013
- Individual Investigator Research Award Cancer Prevention and Research Institute of Texas, 2010
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsOncogenic KRAS requires complete loss of BAP1 function for development of murine intrahepatic cholangiocarcinomaRebecca K. Marcus, Sammy Ferri-Borgogno, Abdel Nasser Hosein, Wai Chin Foo, Bidyut Ghosh
Cancers. 2021-11-15 - 107 citationsModeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.Yi Feng Gu, Shannon M. Cohn, Alana Christie, Tiffani McKenzie, Nicholas C. Wolff
Cancer Discovery. 2017-01-01 - 110 citationsBap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesisShanshan Wang, Yi Feng Gu, Nicholas C. Wolff, Karoliina Stefanius, Alana Christie
Proceedings of the National Academy of Sciences of the United States of America. 2014-11-18
Press Mentions
- Clinical Trials for Kidney Cancer: What to KnowDecember 26th, 2022
- Tackling HIF2 Drug Resistance with an RNA-Based Therapy: NewsroomOctober 3rd, 2022
- Clinical Trial Sets Stage for New Paradigm in Kidney Cancer TreatmentAugust 18th, 2022
- Join now to see all
Grant Support
- Specialized Program of Research Excellence (SPORE)NIH/NCI2016–Present
Committees
- Chair, Scientific Advisory Board, National Kidney Cancer Academy 2020 - Present
- Chair, Congressionally Directed Medical Research Program – Kidney Cancer Research Program 2017 - 2018
Professional Memberships
- Member
- Member
- American Society for Clinical Investigation - ASCIMember
Other Languages
- Spanish
Hospital Affiliations
- University of Texas Southwestern Medical CenterDallas, Texas
External Links
- Kidney Cancer Programhttp://www.utsouthwestern.edu/kidneycancer
- Brugarolas Labhttp://www.brugarolaslab.com
- Kidney Cancer SPOREhttps://trp.cancer.gov/spores/kidney.htm
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: